Polymorphic form of atorvastatin calcium
AssigneeTeva Pharmaceutical Industries Ltd.
InventorsAri Ayalon, Michal Levinger, Sofia Roytblat, Valerie Niddam, Revital Lifshitz, Judith Aronhime
Life of this patent
Estimating the term…
Abstract
The present invention relates to atorvastatin calcium, a useful agent for lowering serum cholesterol levels. New atorvastatin calcium Form V, processes for preparing the new form, and pharmaceutical compositions and dosage forms containing the new form are disclosed.
Claims6
Atorvastatin calcium Form V having an X-ray powder diffractogram substantially as depicted in FIG. 1.
Atorvastatin calcium Form V characterized by X-ray powder diffraction peaks at 5.3±0.2 and 8.3±0.2 degrees 2θ and a broad peak at 18-23±0.2 degrees 2θ with a maximum at 18.3±0.2 degrees 2θ.
Atorvastatin calcium Form V having a solid state 13C NMR spectrum substantially as depicted in FIG. 2.
Atorvastatin calcium Form V characterized by solid state 13C NMR signals at 21.9, 25.9, 118.9, 122.5, 128.7, 161.0 and 167.1 ppm.
Atorvastatin calcium Form V characterized by X-ray powder diffraction peaks at 5.3±0.2 and 8.3±0.2 degrees 2θ and solid state 13C NMR signals at 21.9, 25.9, 118.9, 122.5, 128.7, 161.0 and 167.1 ppm.
Dependencies are inferred from the claim text.